Hi Kate! Dr. Neal Shore, Grand Strand Urology/Atlantic Urology Clinics and Carolina Urologic Research Center have been involved with the Dendreon Corporation since 2003. We participated in the clinical research trials of Provenge, more specifically the 9902B and PB01 trials. Provenge (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. Provenge was approved by the US FDA on April 29, 2010, and we have been infusing Provenge in our clinic since July, 2010. We are huge supporters of the Dendreon Corporation and Provenge. We will gladly assist you and your clinic as you prepare your site and staff to infuse Provenge. Please contact either of us:
[email protected], or
[email protected].